Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01030 ...
Drug Name Topotecan
Molecular Weight 421.4458
Molecular Formula C23H23N3O5
CAS Number 123948-87-8
SMILES CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
External Links
DRUGBANK DB01030
PubChem Compound 60700
PDR 197
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 0.8 - 0.8 - DRUGBANK
Melting Point 215.5 ℃ 213-218 ℃ DRUGBANK
Water Solubility 1000.0 mg/L 1 mg/ml DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 32.0 % 32±12 % PO, oral; adults; solid tumors; The Pharmacological Basis of Therapeutics
C Max 5.9 ng/ml 5.9±0.8 ng/ml Oral single dose; Derivative; adults; solid tumors; The Pharmacological Basis of Therapeutics
C Max 7.5 ng/ml 7.5±2.6 ng/ml Oral single dose; Derivative; adults; solid tumors; The Pharmacological Basis of Therapeutics
C Max 38.0 ng/ml 38±8 ng/ml Derivative; adults; solid tumors; The Pharmacological Basis of Therapeutics
C Max 19.0 ng/ml 19±2 ng/ml Derivative; adults; solid tumors; The Pharmacological Basis of Therapeutics
T Max 0.92 h 0.92±0.61 h Oral single dose; Derivative; adults; solid tumors; The Pharmacological Basis of Therapeutics
T Max 1.8 h 1.5-2 h Oral single dose; Derivative; adults; solid tumors; The Pharmacological Basis of Therapeutics
Clearance 28.6 L/h/m2 28.6±4.1 L/h/m2 tumor; patients; adults; Male, men;  Female, women; Children → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Clearance 0.78 L/h/kg 13 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 74.0 L/m2 74±21 L/m2 tumor; patients; adults; Male, men;  Female, women; The Pharmacological Basis of Therapeutics
Volume of Distribution 1.8 L/kg 1.8 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 2.5 h 2-3 h DRUGBANK
Half-life 2.4 h 2.4±0.4 h RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Half-life 5.7 h 2.9-8.4 h intravenous injection, IV; The Pharmacological Basis of Therapeutics
Half-life 2.3 h 2.3 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 73.4 % 73.4±2.3 % Urinary excretion; Faeces excretion; intravenous injection, IV; tumor; DRUGBANK
Eliminate Route 40.0 % 40 % Urinary excretion; adults; solid tumors; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 35.0 % 35 % DRUGBANK
Protein Binding 21.3 % 21.3 % adults; solid tumors; human, homo sapiens; The Pharmacological Basis of Therapeutics
Protein Binding 6.6 % 6.6 % adults; solid tumors; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 4.0 mg 4 mg intravenous injection, IV Hycamtin Capsules topotecan PDR
Max dose for adults 2.3 mg/m2/day 2.3 mg/m2/day PO, oral Hycamtin Capsules topotecan PDR
Max dose for geriatric 4.0 mg 4 mg intravenous injection, IV Hycamtin Capsules topotecan PDR
Max dose for geriatric 2.3 mg/m2/day 2.3 mg/m2/day PO, oral Hycamtin Capsules topotecan PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1